Skip to main content Skip to main navigation menu Skip to site footer

Efektivitas tatalaksana tas-102 pada pasien kanker kolorektal metastasis



Abstract

Background: Colorectal cancer is uncontrolled cell growth in the colon and rectum. On diagnosis, 20% of patients came with metastasis, and almost 50% will develop into one. On the third line and later, trifluridine/tipiracil (TAS-102) is available for metastatic colorectal cancer. This systematic review aimed to evaluate the efficacy of TAS-102 as monotherapy compared to a placebo or combined with bevacizumab.

Method: Systematic computer-based literature search for randomized controlled trials was conducted from Sept 23 until Oct 1, 2020, on PubMed and ASCO using the keywords (1)‘‘Metastatic Colorectal Cancer”, (2)‘‘TAS-102’’, (3)“management,” “treatment.” Results from the study were taken, such as overall survival and progression-free survival.

Results: From 225 articles on Pubmed and 62 from ASCO, 3 study articles from 2015 – 2020 that fit the inclusion criteria were taken. From 3 articles that match the inclusion criteria, the total population sample was 1299 colorectal cancer patients treated by TAS-102. Two studies compared TAS-102 and placebo showed that TAS-102 effectively increased overall and progression-free survival. The third article compared TAS-102 as monotherapy and, combined with bevacizumab, showed that TAS-102 was effective in improving overall survival and progression-free survival, and bevacizumab was able to increase the effects.

Conclusion: TAS-102 increased overall survival and progression-free survival in patients with metastatic colorectal cancer.

 

Latar Belakang: Kanker kolorektal adalah perkembangan sel-sel pada kolon dan rektum yang tidak terkontrol. Pada saat diagnosis, 20% pasien datang dengan keadaan metastasis dan hampir 50% akan berkembang menjadi metastasis. Pada lini ketiga atau lini lanjut, trifluridine/tipiracil (TAS-102) tersedia untuk pasien kanker kolorektal yang sudah bermetastasis. Systematic review ini bertujuan untuk mengevaluasi efektivitas TAS-102 pada beberapa penelitian yang meneliti TAS-102 sebagai monoterapi dibandingkan dengan plasebo atau dikombinasi dengan bevacizumab.

Metode: Pencarian literatur berupa randomized controlled trial dilakukan berbasis komputer pada tanggal 23 September 2020 hingga 1 Oktober 2020 di PubMed dan ASCO menggunakan kata kunci (1)‘‘Metastatic Colorectal Cancer”, (2)‘‘TAS-102’’, (3)“management”, “treatment”. Hasil artikel penelitian berupa overall survival dan progression-free survival kemudian dicatat.

Hasil: Hasil identifikasi 225 artikel dari Pubmed, 62 dari ASCO didapatkan 3 artikel yang memenuhi kriteria inklusi dan diambil dari kurun waktu tahun 2015 – 2020. Dari 3 artikel penelitian yang memenuhi kriteria inklusi, total populasi sampel 1299 dengan kanker kolorektal metastasis. Dua penelitian yang membandingkan tatalaksana TAS-102 dengan plasebo dan satu penelitian membandingkan TAS-102 sebagai monoterapi dan kombinasi TAS-102 dengan bevacizumab. Ketiga penelitian tersebut menunjukkan bahwa TAS-102 mampu meningkatkan overall survival dan progression-free survival.

Simpulan: TAS-102 mampu meningkatkan overall survival dan progression-free survival pada pasien kanker kolorektal yang sudah bermetastasis.

Keywords: kanker kolorektal metastasis TAS-102 tatalaksana manajemen.

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [published correction appears in CA Cancer J Clin. 2020 Jul;70(4):313]. CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492
  2. Shah MA, Renfro LA, Allegra CJ, et al. Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. J Clin Oncol. 2016;34(8):843-853. doi:10.1200/JCO.2015.63.0558
  3. van der Velden D, Opdam F, Voest E. TAS-102 for Treatment of Advanced Colorectal Cancers That Are No Longer Responding to Other Therapies. Clinical Cancer Research. 2016;22(12):2835-2839
  4. Miyamoto Y, Lenz HJ, Baba H. A novel antimetabolite: TAS-102 for metastatic colorectal cancer. Expert Rev Clin Pharmacol. 2016;9(3):355-365. doi:10.1586/17512433.2016.1133285
  5. Lenz HJ, Stintzing S, Loupakis F. TAS-102, a novel antitumor agent: a review of the mechanism of action. Cancer Treat Rev. 2015;41(9):777-783. doi:10.1016/j.ctrv.2015.06.001
  6. van der Velden, D., Opdam, F. dan Opdam, F. TAS-102 and the quest for predictive biomarkers. ESMO Open, 2017;2(4), p.e000263.
  7. Mayer, R., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., Sobrero, A., Boucher, E., Peeters, M., Tran, B., Lenz, H., Zaniboni, A., Hochster, H., Cleary, J., Prenen, H., Benedetti, F., Mizuguchi, H., Makris, L., Ito, M. and Ohtsu, A. Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer. New England Journal of Medicine, 2015;372(20), pp.1909-1919. Tersedia di : doi: 10.1056/nejmoa1414325. [diunduh: 10 Oktober 2020].
  8. Xu J, Kim TW, Shen L, et al. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study. J Clin Oncol. 2018;36(4):350-358. doi:10.1200/JCO.2017.74.3245
  9. Pfeiffer P, Yilmaz M, Möller S, et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21(3):412-420. doi:10.1016/S1470-2045(19)30827-7
  10. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-E386. doi:10.1002/ijc.29210
  11. Favoriti P, Carbone G, Greco M, Pirozzi F, Pirozzi RE, Corcione F. Worldwide burden of colorectal cancer: a review. Updates Surg. 2016;68(1):7-11. doi:10.1007/s13304-016-0359-y
  12. Modest DP, Pant S, Sartore-Bianchi A. Treatment sequencing in metastatic colorectal cancer. Eur J Cancer. 2019;109:70-83. doi:10.1016/j.ejca.2018.12.019
  13. Yoshino T, Mizunuma N, Yamazaki K, et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2012;13(10):993-1001. doi:10.1016/S1470-2045(12)70345-5
  14. Kuboki Y, Nishina T, Shinozaki E, et al. TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. Lancet Oncol. 2017;18(9):1172-1181. doi:10.1016/S1470-2045(17)30425-4
  15. Tsukihara H, Nakagawa F, Sakamoto K, et al. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts. Oncol Rep. 2015;33(5):2135-2142. doi:10.3892/or.2015.3876
  16. Matsuhashi N, Takahashi T, Fujii H, et al. Combination chemotherapy with TAS-102 plus bevacizumab in salvage-line treatment of metastatic colorectal cancer: A single-center, retrospective study examining the prognostic value of the modified Glasgow Prognostic Score in salvage-line therapy of metastatic colorectal cancer. Mol Clin Oncol. 2019;11(4):390-396. doi:10.3892/mco.2019.1899
  17. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303-312. doi:10.1016/S0140-6736(12)61900-X
  18. Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J, Kim TW; CONCUR Investigators. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015 Jun;16(6):619-29. doi: 10.1016/S1470-2045(15)70156-7. Epub 2015 May 13. PMID: 25981818.
  19. Masuishi T, Taniguchi H, Hamauchi S, Komori A, Kito Y, Narita Y, Tsushima T, Ishihara M, Todaka A, Tanaka T, Yokota T, Kadowaki S, Machida N, Ura T, Fukutomi A, Ando M, Onozawa Y, Tajika M, Yasui H, Muro K, Mori K, Yamazaki K. Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison. Clin Colorectal Cancer. 2017 Jun;16(2):e15-e22. doi: 10.1016/j.clcc.2016.07.019. Epub 2016 Aug 31. PMID: 27670892.

How to Cite

Cassidy, C. A., Dewi, N. N. A., Sutadarma, I. W. G., & Wiryanthini, I. A. D. (2021). Efektivitas tatalaksana tas-102 pada pasien kanker kolorektal metastasis. Intisari Sains Medis, 12(3), 1058–1063. https://doi.org/10.15562/ism.v12i3.931
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
0

Total
0

Share

Search Panel

Christian Axel Cassidy
Google Scholar
Pubmed
ISM Journal

Ni Nyoman Ayu Dewi
Google Scholar
Pubmed
ISM Journal

I Wayan Gede Sutadarma
Google Scholar
Pubmed
ISM Journal

Ida Ayu Dewi Wiryanthini
Google Scholar
Pubmed
ISM Journal